The two pharma companies will work together to market treatments for hepatitis C in the U.S. The companies will promote Merck's boceprevir with an older drug from Roche to a market that will be worth
$15 billion by 2019. The companies' researchers will also collaborate on drug cocktails to fight hep C, which over time can destroy the liver. Regulators approved boceprevir this month.
Read the whole story at Bloomberg »
